Days after hitting the market, the new pill version of Novo Nordisk’s wildly in style weight-loss drug will probably be obtainable by way of Amazon’s on-line pharmacy.
Amazon joins telehealth suppliers, low cost prescription stalwart GoodRx, and even Novo Nordisk itself in offering the novel weight-management drug for shoppers who wish to pay out of pocket.
With the introduction of the oral model of Wegovy, the weight-loss medication which have taken the world by storm will develop into much more accessible—and extra available for anybody who pays out of pocket.
The oral model of Wegovy will begin at $149 a month out of pocket by way of Amazon Pharmacy, and can value $25 a month with eligible insurance coverage protection. The 1.5-milligram and 4-milligram “starter” doses of Wegovy are priced at $149 per thirty days, with the upper doses that many individuals transfer as much as priced round $299.
“We all know there are people who find themselves keen on addressing their weight however have been ready on the sidelines for a medication that was proper for them,” Novo Nordisk marketing and affected person options SVP Ed Cinca stated in a press release. “For a lot of of them, that wait is over.”
Rivals race to market with a weight-loss tablet
The 2 corporations that launched the world to the GLP-1 diabetes and weight-loss medication semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro and Zepbound) in injectionable type have been racing to market with a tablet model of their hit medication. Late last month, Novo Nordisk secured Meals and Drug Administration (FDA) approval first, beating its rival drugmaker Eli Lilly, which expects its personal drug to get the inexperienced mild in March.
The Danish drugmaker was additionally first to market with the injectable model of its weight-loss drug Wegovy, however it struggled on the manufacturing facet when a large wave of demand outstripped provide. That dynamic allowed Eli Lilly to realize floor with its personal weight-management drug, Zepbound, and pushed the American drugmaker’s inventory to new heights.
In November, Novo Nordisk and Eli Lilly announced a take care of the Trump administration to make their upcoming weight-loss drugs obtainable for $149 out of pocket. Underneath the phrases of the deal, a part of the White Home’s wider negotiation on drug prices, each corporations will probably be exempt from tariffs on pharmaceutical merchandise for 3 years.
Past Amazon Pharmacy, Novo’s weight-loss tablet may even be coming to TrumpRx, the Trump administration’s upcoming portal that can join shoppers with drugmakers to decrease costs. “For a few years, Individuals have paid the very best costs wherever on the planet for pharmaceuticals—rather more than different nations for the very same product,” Trump stated in a quote featured on the TrumpRx placeholder site. “That ends right now.” TrumpRx is anticipated to launch in early 2026.
Dr. Amazon will see you now
In case you’re confused that Amazon is suddenly a healthcare provider, you’re most likely not alone. The corporate finest recognized for its sprawling on-line storefront and ubiquitous supply vans jumped into the prescription drug enterprise in 2020 when it launched its personal on-line pharmacy, which grew out of a earlier acquisition of an organization known as PillPack.
In 2022, Amazon expanded its well being ambitions by shopping for subscription-based main care and telehealth supplier One Medical for $3.9 billion. Final month, the tech big launched a community of drug-vending kiosks, bringing its signature robotic touch to the pharmacy. The drug merchandising machines, situated in some One Medical places of work, are a no-footprint reply to major store closures from longtime drugstore corporations like Walgreens, Ceremony Support, and CVS.
With widespread patient-initiated telehealth and cheaper weight-loss medication coming out of merchandising machines, the way forward for drugs is, for higher or worse, trying much more like the long run in 2026.
